FangSheng Pharmaceutical

Company Deals

Hunan FangSheng Pharmaceutical to Acquire JAK Inhibitor Patent Rights for RMB 80 Million

Fineline Cube Aug 20, 2025

Hunan FangSheng Pharmaceutical Co., Ltd. (SHA: 603998) announced today that it has reached an agreement...

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod